The addition of utomilumab after infusion with axicabtagene ciloleucel induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed.
Early results from the phase 1 study — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — suggest utomilumab (PF-05082566, Pfizer) may enhance the expansion and function of axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) to improve clinical outcomes.
Axicabtagene ciloleucel — also known as axi-cel — is an